Extended Data Figure 1 | Sequence conservation of CRBN. a, Alignment of G. gallus CRBN and human CRBN; the Zn 21 -coordinating domain and residues involved in compound binding are highlighted in yellow and cyan, respectively. The secondary structure of the CRBN protein is shown at the top. b, Surface representation of CRBN orthologues highlighting the evolutionarily conserved residues (sequences used for the alignment include Homo sapiens,
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the teratogenicity of thalidomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletionassociated dysplasia. IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4 CRBN ) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4 CRBN . Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide. The structure establishes that CRBN is a substrate receptor within CRL4 CRBN and enantioselectively binds IMiDs. Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4 CRBN . Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4 CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degradation. This dual activity implies that small molecules can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.
Thalidomide (a-(N-phthalimido)glutarimide) was introduced to the market in 1954 by the company Chemie Grünenthal. Initially promoted as a sedative with anti-emetic properties 1,2 , it became popular for treating 'morning sickness' 3 . In 1961, thalidomide taken in the first trimester of pregnancy was implicated in frequent limb deformities in infants 4, 5 . Between 8,000 and 12,000 affected children were born before the drug was banned. Interest in thalidomide revived in 1965, when it was shown to have immunomodulatory and anti-inflammatory properties in patients with erythema nodosum leprosum, an inflammatory complication of leprosy 6 . In 1994, thalidomide was found to inhibit the basic fibroblast growth factor (bFGF)-induced formation of new blood vessels 7 . These findings prompted clinical trials exploring thalidomide use for anti-angiogenic cancer therapy. The efficacy of thalidomide and its derivatives lenalidomide and pomalidomide (collectively known as IMiDs) has since been demonstrated for several haematological cancers 8 : newly diagnosed multiple myeloma (thalidomide) 9 , refractory multiple myeloma (lenalidomide or pomalidomide) and 5q-deletion-associated myelodysplastic syndrome (lenalidomide).
The target of thalidomide, cereblon (CRBN), is a ubiquitously expressed protein that is part of the cullin-4-containing E3 ubiquitin ligase complex CUL4-RBX1-DDB1 (known as CRL4) 10 . Mutations in CRBN are associated with autosomal recessive, non-syndromic mental retardation 11 . In myeloma cells, the anti-proliferative activities of IMiDs are linked to CRBN expression 12, 13 , making IMiDs the first clinically approved drug targeted at E3 ubiquitin ligases with specificity for CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) 12 . The anti-proliferative and immunomodulatory effects of IMiDs have recently been linked to drug-induced ubiquitination and degradation of the transcription factors IKZF1 (also known as IKAROS) and IKZF3 (also known as AIOLOS) by CRL4 CRBN (refs [14] [15] [16] . Accordingly, loss of CRBN is a common determinant of drug resistance in myeloma cells 12 . How IMiD binding affects CRL4 CRBN at the molecular level remains unclear. We set out to examine the role of CRBN within the E3 ubiquitin ligase complex CRL4 CRBN , characterizing the effect of IMiD binding on ligase activity.
Structure of DDB1-CRBN bound to IMiDs
We crystallized a chimaeric complex of human DDB1 and Gallus gallus (chicken) CRBN bound to thalidomide (refined to 3.0 Å ), lenalidomide (3.0 Å ) and pomalidomide (3.5 Å ) ( Fig. 1a, b and Extended Data Table 1 ). The high level of sequence conservation between human and chicken CRBN (Extended Data Fig. 1a , b) allows structural insight into human CRBN to be inferred directly from G. gallus CRBN. All subsequent biochemical and cell-biological experiments were performed with full-length human proteins. G. gallus CRBN consists of three sub-domains (Extended Data Fig. 2a-f ): a seven-stranded b-sheet located in the amino-terminal domain (NTD, residues 1-185) (Extended Data Fig. 2a ), a seven a-helical bundle domain (HBD, residues 186-317) involved in DDB1 binding (Fig. 1c) , and a carboxy-terminal domain composed of eight b-sheets (CTD, residues 318-445) ( Fig. 1b ). DDB1 comprises three seven-bladed WD40 b-propellers (BPA, BPB and BPC) arranged in a triangular fashion 17 , with G. gallus CRBN attaching to a cavity between the BPA and BPC propellers (Fig. 1c ). The molecular basis of the HBD-mediated attachment of G. gallus CRBN to DDB1 defines a novel class of DDB1 binders and differs in detail from previously reported DDB1 attachment modules [17] [18] [19] [20] (Extended Data Fig. 2e, f) .
The G. gallus CRBN N-terminal region (residues 46-317), including the NTD and HBD, resembles the N-terminal domain of bacterial Lon proteases (Protein Data Bank (PDB) ID 3LJC; root mean squared deviation (r.m.s.d.), 2.7 Å over 178 residues aligned) (Extended Data Fig. 2b ). The CTD harbours the thalidomide-binding pocket and contains a conserved Zn 21 -binding site, which is situated approximately 18 Å from the IMiD (Fig. 1a, b ). The Zn 21 ion is coordinated through conserved cysteine residues 325, 328, 393 and 396. The G. gallus CRBN-CTD shares structural similarity with the pseudouridine synthase and archaeosine transglycosylase (PUA) fold family 21 , which are involved in binding diverse sets of ligands (Extended Data Fig. 2c, d ).
IMiD binding to CRBN
Thalidomide, lenalidomide and pomalidomide ( Fig. 2a -c and Extended Data Fig. 3a -i) bind a pocket on G. gallus CRBN-CTD ( Fig. 1b ) situated in a surface groove that is highly conserved across CRBN orthologues (Extended Data Fig. 1b ). The three ligands superimpose with very little deviation in the a-(isoindolinone-2-yl) glutarimide moiety, which contributes the majority of interactions between the receptor and the compounds and is the main pharmacophore 22 . The glutarimide group is held in a buried cavity between G. gallus CRBN sheets b10 and b13 (Fig. 2d ). The glutarimide carbonyls (C2 and C6) and the intervening amide (N1) are in hydrogen-bonding distance with G. gallus CRBN residues His 380 and Trp 382, respectively ( Fig. 2c, d) . A delocalized lone pair connects the glutarimide nitrogen with the two glutarimide carbonyls (C2-N1-C6) and is coplanar with Trp 382. The opposing aliphatic face of the glutarimide ring (C3, C4 and C5) is in tight van der Waals contact with a hydrophobic pocket lined by Trp 382, Trp 388, Trp 402 and Phe 404. In vitro, mutations of Tyr 386 (which affect the integrity of the binding pocket) and Trp 388 (which is directly involved in compound binding) to alanine ablate the binding of all three IMiDs to CRBN 10 (Extended Data Fig. 4a -c). Mutations of the equivalent residues render CRL4 CRBN insensitive to the presence of thalidomide or lenalidomide in vivo 10, 12 . In addition to the almost identical binding modes, we found that thalidomide, lenalidomide and pomalidomide have similar affinities for CRBN, with dissociation constants of ,250 nM, ,178 nM and ,157 nM, respectively (Extended Data Fig. 4d -h).
Thalidomide differs from lenalidomide and pomalidomide in the C4 phthalimide aniline functionality ( Fig. 2a-c ), which is found in a solventexposed position. The common carbonyl at the phthaloyl C1 position contributes a water-mediated hydrogen bond to His 359, which anchors the phthaloyl ring system together with stacking interactions provided by the aliphatic face of Pro 354 (Fig. 2d ). The phthalimide C5 and C6 positions are fully solvent exposed. The overall shape of the buried IMiD-binding pocket favours binding of the (S)-enantiomer over the (R)-enantiomer ( Fig. 2e ), which is in agreement with in vivo experiments 12 .
CRBN functions as a DCAF for the ligase CRL4 CRBN
Within the CRL4 family of ligases, DDB1 functions as the adaptor connecting the substrate receptor to the ligase CUL4 (refs 17, 19, 23) . More than a dozen substrate receptors, including CRBN, have been identified (and these are designated DCAFs for DDB1-and CUL4-associated factors). G. gallus CRBN, despite lacking the canonical DCAF WD40 fold, resembles a substrate receptor in its dimensions and position on DDB1 (Extended Data Fig. 5a, b ). The thalidomide-binding site is situated where substrates generally bind to WD40 DCAFs (see, for example, DDB2 engaging DNA ( Fig. 3a and Extended Data Fig. 5a, b) ). The equivalent residues in the structurally related PUA-domain-containing proteins are directly engaged in ligand binding (Extended Data Fig. 5c-e ). The PUA domain of CRBN has striking structural similarity to a member of the methionine sulphoxide reductase family (Extended Data Fig. 2c, d ). In G. gallus CRBN, the now defunct active centre of the reductase interacts with IMiDs. Truncation of the CRBN C terminus bordering the conserved thalidomide-binding pocket has been found in non-syndromic mental retardation (see Extended Data Fig. 6a -c for analysis of CRBN mutations).
Within CUL4-RBX1-DDB1-DCAF complexes, CUL4 was found to freely rotate up to 150u around DDB1 (refs 24, 25) ( Fig. 3a, b ). CUL4 mobility is undirected and is driven exclusively by Brownian motion. Given the strictly modular architecture of the CRL4 family [23] [24] [25] , the structure 
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of CRL4 CRBN can be predicted with high confidence (Fig. 3b ). Rotation of the ligase arm of CUL4 around DDB1 and CRBN establishes a ubiquitination zone with dimensions of up to 340 Å 3 110 Å 3 30 Å (Fig. 3b) , with the centre of rotation near the thalidomide-binding site. The CRL4 ligase is promiscuous, targeting lysines that cross this ubiquitination zone. Accordingly, we observed that CRBN is autoubiquitinated in vitro (Extended Data Fig. 7a-d) at the unstructured N-terminal tail 26 (residues Lys 39 and Lys 43; see also Extended Data Fig. 7d ). We found that CRBN autoubiquitination persisted in the presence of IMiDs in vitro (Extended Data Fig. 7b ) and was subject to inhibition by the Cop9 signalosome (CSN) (Extended Data Fig. 7b, c) .
Pomalidomide and lenalidomide effectively target the IKAROS transcription factors IKZF1 and IKZF3 for degradation by CRL4 CRBN . Thalidomide, by contrast, is here less efficient [14] [15] [16] (Fig. 3c ). All three IMiDs have comparable affinities for CRBN (Extended Data Fig. 4e -h) and similar predicted membrane permeabilities (Extended Data Fig. 7e ). The major structural difference between CRBN-bound lenalidomide and pomalidomide and CRBN-bound thalidomide lies in the presence of the solvent-exposed C4 aniline functionality in lenalidomide and pomalidomide. Therefore, different functional groups at the phthaloyl C4, C5 and C6 positions were tested for their ability to degrade IKZF1 in a dual luciferase reporter assay 14 (see Supplementary Methods). Small groups attached to C4 of thalidomide (NH 2 , CH 3 and to some extent Cl) promoted IKZF1 degradation (Fig. 3c ). By contrast, larger substituents at the C4, C5, or C4 and C6 positions were less effective at promoting IKZF1 degradation. These modifications are not expected to affect CRBN binding, as even a large substituent at the C4 position had no adverse effect on affinity (Extended Data Fig. 4d ). Assuming comparable cellular concentrations [27] [28] [29] , this finding indicates that solvent-exposed bulky groups at C4 (and methyl groups at C5 and C6) interfere with IKZF1 binding. The aniline and methyl substituents at C4, however, appear to contribute to IKZF1 degradation, probably through direct interactions.
MEIS2 is an endogenous ligase substrate of CRL4 CRBN Next, we set out to examine the effects of IMiDs on endogenous CRBN substrates, which have so far remained elusive. An unbiased biochemical screen was established to identify proteins that are ubiquitinated by CRL4 CRBN . Human protein microarrays (,9,000 proteins) were used for on-chip ubiquitination by the complex CUL4A-RBX1-DDB1-CRBN (CRL4A CRBN ) in the presence of E1 (UBA1), E2 (UBCH5A), ubiquitin (biotin-ubiquitin) and ATP (Extended Data Fig. 8a-e ). We reasoned that a substrate would be subject to ubiquitination by CRL4A CRBN but not by a control ligase (CRL4A CDT2 ), that a substrate would overcome inhibition of CRL4A CRBN by CSN 24 and that ubiquitination of such substrates would be inhibited by lenalidomide. Following cluster analysis (43 clusters), we identified one cluster that best matched the expected ubiquitination profile (see Supplementary Methods for details). In an orthogonal screen, the top five candidate genes (GRINL1A, MBOAT7, OTUD7B, C6orf141 and MEIS2) were overexpressed in HEK 293T cells and assessed for lenalidomide-induced changes in steady-state levels (Extended Data Fig. 8f ). Of these factors, we focused on MEIS2, a transcription factor that has been implicated in various aspects of human development [30] [31] [32] , which we found was stabilized on lenalidomide treatment (see below).
To recapitulate the on-chip results in solution, insect-cell-derived MEIS2 was used to establish a fully recombinant CRL4 CRBN ubiquitination system. MEIS2 expressed from insect cells was isolated in a hyperphosphorylated form. Dephosphorylation was found to improve protein behaviour, resulting in increased MEIS2 ubiquitination using lysine-free (K0) ubiquitin (Fig. 4a, compare lanes 1 and 2) . MEIS2 ubiquitination was also observed using phosphorylated MEIS2 (data not shown). MEIS2 ubiquitination by CRL4 CRBN was subject to inhibition by various IMiDs (Fig. 4a, lanes 4-8, and Extended Data Fig. 9a ), irrespective of the chemical substituent at the C4, C5 or C6 position. A CRL4 CRBN mutant carrying the Tyr384Ala and Trp386Ala substitutions (CRBN YW/AA ) that rendered the receptor unable to bind IMiDs (Extended Data Fig. 4a-c) 
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MEIS2 ubiquitination (Extended Data Fig. 9b ). In accordance with our onchip results, we found that MEIS2 can relieve the inhibition of CRL4 CRBN by CSN (Extended Data Fig. 9c ) and is not ubiquitinated by the control ligases CRL4 CSA and CRL4 CDT2 (Extended Data Fig. 9d ). These data suggest that, within the CRL4 CRBN complex, CRBN targets MEIS2 for ubiquitination in vitro with the aid of its IMiD-binding site.
We next sought to test the effect of lenalidomide on MEIS2 half-life in cells by performing cycloheximide (CHX) chase experiments. RNAseq data from The Cancer Genome Atlas (TCGA) identified the neuroblastoma cell line SK-N-DZ as having high levels of endogenous MEIS2 and CRBN transcripts. Following treatment with 100 mg ml 21 CHX, we found that MEIS2 protein levels were largely depleted after 3 h (Fig. 4b, lanes 1-4) . The addition of 10 mM lenalidomide stabilized MEIS2 protein levels under these conditions (Fig. 4b, lanes 5-8) . As SK-N-DZ cells were recalcitrant to transfection, we subsequently employed M059J cells, which are similarly characterized by high levels of MEIS2 messenger RNA (TCGA), to examine the effects of CRBN depletion by RNA interference on MEIS2 abundance. For all of the experiments, the endogenous MEIS2 levels were monitored by quantitative immunoblotting using infrared detection (see Extended Data Fig. 9e-p) . M059J or HEK 293T cells were transfected with four short interfering RNAs, resulting in efficient CRBN knockdown ( Fig. 4c ) and increased MEIS2 steadystate levels in M059J cells ( Fig. 4c ) and HEK 293T cells (data not shown), implicating CRBN in MEIS2 turnover.
To test whether lenalidomide treatment results in increased steadystate levels of MEIS2, M059J cells were treated with lenalidomide or a dimethyl sulphoxide (DMSO) control. Following lenalidomide treatment, endogenous MEIS2 protein levels were elevated by up to 2.5-fold ( Fig. 4d and Extended Data Fig. 9i-k) . A similar level of steady-state MEIS2 stabilization was observed with MLN4924 (Extended Data Fig. 9i, lane 6) , a NEDD8-activating enzyme inhibitor, and with the proteasome inhibitor bortezomib (Extended Data Fig. 9i, lane 5) . Increases in MEIS2 protein levels following lenalidomide exposure were not due to mRNA changes, as determined by quantitative reverse transcription PCR (RT-PCR) (Extended Data Fig. 9m ).
When examining different IMiD derivatives, we found that thalidomide, lenalidomide and pomalidomide stabilized steady-state MEIS2 protein levels to a similar extent ( Fig. 4d and Extended Data Fig. 9i, k) . The effect of thalidomide on MEIS2 levels was also observed in vivo: whole zebrafish embryos 24 h post fertilization showed a 1.5-fold increase in MEIS2 levels, comparable to that observed in the cell lines (Extended Data Fig. 9l ).
Thalidomide is an agonist and an antagonist
We found that IMiD binding and MEIS2 recruitment were mutually exclusive in vitro and in vivo (Figs 4a and 5a -c and Extended Data Fig. 9b ). Accordingly, a stable cell line overexpressing an epitope-tagged MEIS2 together with the CRBN YW/AA mutant (Extended Data Fig. 9f , g) exhibited no changes in MEIS2 levels following the addition of 40 mM lenalidomide. MEIS2 is thus an endogenous, IMiD-sensitive target of CRBN (see Supplementary Discussion for the putative role of MEIS2 in IMiD-mediated teratogenicity). Most CRLs studied so far target multiple substrates 33, 34 . Given that IMiDs occupy the canonical ligand interface of the CRBN PUA domain, we also expect that other endogenous substrates are prevented from CRBN binding by thalidomide and its derivatives. By contrast, IMiD-dependent targeting of the IKAROS transcription factors (Fig. 5d ) is facilitated by specific solvent-exposed functionalities that are not involved in CRBN binding. We propose a model in which the interaction surface used for IKAROS family member binding comprises CRBN (in its IMiD-bound form) and the C4, C5 and C6 phthaloyl positions of the IMiD. While structural studies on CRBN-IMiD-IKAROS complexes are necessary to shed light on the details of the binding mode, conceptually this mechanism bears striking similarities to auxin-induced degradation of members of the Aux/IAA repressor family by the ligase TIR1 (ref. 35 ) and to cyclosporin-A-induced cyclophilin binding (or FK506-induced FKBP12 binding) to calcineurin 36, 37 . The CRL4 architecture supports ubiquitination in its vicinity, a property that is exploited by viral proteins in recruiting cellular targets for degradation by CRL4s 17 . As small molecules can apparently mimic this behaviour, it will be important to explore whether synthetic small molecules can promote the degradation of other substrates that are not typically targeted by a specific ubiquitin ligase.
Our structure-function analysis indicates that IMiD-mediated IKAROS transcription factor degradation simultaneously interferes with the recruitment of endogenous substrates (such as MEIS2) to CRL4 CRBN . Depending on the cell type and the proteins expressed, the administration of thalidomide and its derivatives will thus simultaneously affect the levels of two groups of proteins: upregulating the endogenous substrates while decreasing the amounts of neo-substrates. Thalidomide and its IMiD derivatives give rise to pleiotropic clinical effects, ranging from anti-cancer and immunomodulatory properties to pronounced teratogenicity. Both loss of ubiquitination, as seen for MEIS2, and gain of function, as seen for IKAROS family members, and even complex synthetic combinations of these opposing changes, need to be considered as underlying causes of these diverse clinical effects.
METHODS SUMMARY
All recombinant protein complexes were produced in insect cells 25 . The crystal structures of human DDB1 and G. gallus CRBN were determined by molecular replacement with a DDB1 search model and subsequent iterative model building for CRBN. In vitro ubiquitination assays were performed as previously described 25 . Protein-array-based ubiquitin ligase profiling was performed using ProtoArray v5.0 (Life Technologies) and analysed with the R software package. Cell-biological experiments were performed following standard procedures. Binding assays were based on time-resolved fluorescence resonance energy transfer (TR-FRET) or fluorescence polarization methods.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. CRBN at the canonical substrate-binding site. b, The potent anti-myeloma drug thalidomide and its derivatives lenalidomide and pomalidomide occupy the same site but with different solvent-exposed moieties. c, Binding of the endogenous substrate MEIS2 and the IMiDs to this site is mutually exclusive. d, We propose a direct interaction of the C4 amine of lenalidomide or pomalidomide with IKAROS transcription factors (IKZF1 and IKZF3). The binding of these factors probably also involves the surrounding residues of CRBN. How Lon proteases recognize their substrates is unclear at present. As both the NTD and the HBD are present in the Lon fold, it is conceivable that CRBN originated from a fusion of a Lon protease with a PUA-fold-containing enzyme (see below). In the course of divergent evolution, the helical element of the Lon fold appeared to be used for DDB1 binding. c, The G. gallus CRBN C-terminal domain (CTD; residues 318-445) harbours the thalidomide, lenalidomide or pomalidomide-binding pocket and displays structural similarity to PUA folds. Alignment with the methionine sulphoxide reductase family, the closest structural orthologue of G. gallus CRBN (PDB 3MAO; r.m.s.d., 2.0 Å over 79 residues) is shown. The PUA domain fold family frequently carries a conserved metal coordination site, which in G. gallus CRBN appears to bind Zn 21 10 helix located at the central cavity of the WD40 propeller, on the narrow side of the WD40 propeller cone, where ligands typically bind. f, G. gallus CRBN binding to DDB1 differs from that previously seen for DCAF-DDB1 complexes, for which the majority of interactions outside the WD40 propeller domain originated from a consecutive helix-loop-helix (HLH) motif that predominantly contacts DDB1-BPC (golden-brown surface). Extensive interactions between a DCAF and the DDB1-BPA domain (red surface) have not been observed previously, in either the DDB1 co-crystal structures with DDB2 (PDB ID 3EI3; green) or CSA (PDB ID 4A11; dark blue) or other HLH motifs to which DDB1 binds. The novel DDB1-binding mode found in CRBN precluded prior sequence-based identification and suggests considerable plasticity of DCAF binding to DDB1.
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Extended Data Figure 6 | Mutations in CRBN are found in mental retardation and cancer. a, Mutations in CRBN that are associated with mental retardation (indicated in red) and found in cancer (shown as sticks in magenta). CRBN was first identified as a gene that was mutated in a mild form of mental retardation 11 . The identified nonsense mutation causes a premature stop codon after Arg 419, resulting in a truncated form of CRBN. When tested in cells, the truncated CRBN bound to DDB1 but exhibited a higher rate of autoubiquitination 40 . b, In analogy, we found that a recombinant G. gallus CRBN construct (1-426) apparently remained properly folded in vitro, with no obvious association of heat-shock factors. This construct was also capable of forming complexes with DDB1. Two structural rationales that are not mutually exclusive can be proposed for the detrimental effect of the truncation seen in non-syndromic mental retardation. First, the conserved C terminus may be involved in substrate binding; in addition, the absence of the C terminus could also give rise to temporary unfolding that impinges on the ubiquitination zone and thus renders CRBN subject to CRL4 CRBN ubiquitination. Second, the removal of the CRBN C-terminal tail could also delete the binding site for a potential de-ubiquitination enzyme that frequently appears bound at the tails of CRL4 substrate receptors, thus counteracting receptor autoubiquitination; DDB2 is complexed to USP24 (ref. 41 ) and CSA in conjunction with USP7 (ref. 42) . c, The Catalogue of Somatic Mutations in Cancer (COSMIC) database 43 reports a number of somatic mutations in the CRBN gene in various tumours: one nonsense mutation (p.Glu 106*) and seven missense substitutions have been reported. The structure now provides a molecular rationale for the reported mutations. The premature stop codon after Glu 106 probably leads to an unfolded protein or at least abolishes the interaction with DDB1, resulting in a phenotype similar to a total loss of CRBN expression. Trp224Leu and Asn236Thr are surface-exposed residues involved in DDB1 binding, probably weakening this interaction. The Thr119Ala and Asp249Asn mutations affect the core of the protein and probably impair correct folding. The mutations Glu132Lys, Leu168Pro and Thr403Met are surface mutations and could be involved in substrate binding. 
